Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 2/20 | 0.54 |
| ▸ | CTSK | P43235 | 9/20 | 0.52 |
| ▸ | MMP3 | P08254 | 4/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.49 |
| ▸ | CTSL | P07711 | 4/20 | 0.49 |
| ▸ | CTSS | P25774 | 1/20 | 0.49 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.48 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29308018 | 0.90 | SIRT2 (0.52) | SIRT5 | |
| SCHEMBL29360420 | 0.88 | MMP3 (0.58) | CTSKMMP3MMP1CTSLCTSS | |
| SCHEMBL30643726 | 0.86 | PTPN1 (0.49) | PSMB5MMP3 | |
| SCHEMBL29115274 | 0.86 | PTPN1 (0.49) | PSMB5MMP3 | |
| SCHEMBL29115273 | 0.86 | PTPN1 (0.49) | PSMB5MMP3 | |
| SCHEMBL29308943 | 0.85 | REN (0.44) | PSMB5MMP3MMP1 | |
| SCHEMBL2670274 | 0.85 | CASP3 (0.51) | CTSKMMP3SIRT5 | |
| SCHEMBL2670268 | 0.85 | CASP3 (0.51) | CTSKMMP3SIRT5 | |
| SCHEMBL9819550 | 0.84 | CTSK (0.63) | PSMB5CTSKCTSLCTSSCAPN1 | |
| SCHEMBL30480137 | 0.84 | CTSK (0.60) | PSMB5CTSKCTSLCTSSCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | SEAGEN INC. (US) | 2024-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12036286-B2 | Selective drug release from internalized conjugates of biologically active compounds | CTSB, CTSE, CTSZ | PSMB5 594/4885CTSK 11/4885MMP3 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.